Literature DB >> 17591569

Primary central nervous system lymphoma.

Nimish A Mohile1, Lauren E Abrey.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma (NHL) that is restricted entirely to the brain, leptomeninges, eyes, and rarely the spinal cord. It typically presents with focal neurologic symptoms and is characterized by diffuse infiltration of the brain. Corticosteroids are useful for symptomatic treatment but can interfere with definitive pathological diagnosis. PCNSL is radiosensitive and responds to whole-brain radiotherapy. The use of preirradiation high-dose methotrexate-based regimens has significantly improved response rates and patient survival. Longer survival, however, is often marred by devastating neurotoxicity to which the elderly are particularly susceptible. Newer regimens aim to minimize such toxicity while maintaining the survival benefit of combined modality treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591569     DOI: 10.1016/j.semradonc.2007.02.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  8 in total

Review 1.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

2.  Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.

Authors:  Rong Wang; Wenli Chen; Qiang Zhang; Yong Liu; Xiaoyun Qiao; Kui Meng; Ying Mao
Journal:  J Neurooncol       Date:  2014-12-19       Impact factor: 4.130

Review 3.  Intramedullary lesions of the conus medullaris: differential diagnosis and surgical management.

Authors:  Florian H Ebner; Florian Roser; Marcus A Acioly; Wolfgang Schoeber; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2008-09-27       Impact factor: 3.042

4.  O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Authors:  Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman
Journal:  J Neurooncol       Date:  2013-05-18       Impact factor: 4.130

Review 5.  TOX gene: a novel target for human cancer gene therapy.

Authors:  Xin Yu; Zheng Li
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

Review 6.  Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.

Authors:  Lois A Lampson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

7.  Multiparametric MR Imaging Features of Primary CNS Lymphomas.

Authors:  Rustam Talybov; Ozal Beylerli; Vadim Mochalov; Alexey Prokopenko; Tatiana Ilyasova; Tatiana Trofimova; Albert Sufianov; Yang Guang
Journal:  Front Surg       Date:  2022-04-18

8.  Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma.

Authors:  Soheil Zorofchian; Guangrong Lu; Jay-Jiguang Zhu; Dzifa Y Duose; Justin Windham; Yoshua Esquenazi; Leomar Y Ballester
Journal:  Front Oncol       Date:  2018-09-20       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.